Please Wait
Applying Filters...
menu
    • menu
    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Lisaftoclax

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    China NMPA Approves Ascentage Pharma's Lisaftoclax
    China NMPA Approves Ascentage Pharma's Lisaftoclax

    10 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/10/3113419/0/en/Ascentage-Pharma-Announces-Its-Novel-Bcl-2-Inhibitor-Lisaftoclax-Approved-by-China-NMPA-Ushering-in-a-New-Era-for-the-Treatment-of-CLL-SLL.html

    GLOBENEWSWIRE
    10 Jul 2025
    Share Share
    Ascentage Pharma's Assets to be Presented at 2025 EHA Congress
    Ascentage Pharma's Assets to be Presented at 2025 EHA Congress

    09 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/09/3096252/0/en/Thirteen-Studies-of-Ascentage-Pharma-s-Assets-Including-Olverembatinib-and-Lisaftoclax-Selected-for-Presentations-at-2025-European-Hematology-Association-Annual-Congress.html

    GLOBENEWSWIRE
    09 Jun 2025
    Share Share
    Ascentage Pharma presents Lisaftoclax data at ASCO 2025
    Ascentage Pharma presents Lisaftoclax data at ASCO 2025

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3092404/0/en/Live-from-ASCO-2025-Ascentage-Pharma-Presents-Clinical-Data-on-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Refractory-Patients-in-Oral-Report.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064563/0/en/Ascentage-Pharma-Announces-Inclusion-of-Lisaftoclax-and-Olverembatinib-in-Chinese-Society-of-Clinical-Oncology-CSCO-2025-Guidelines.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    Ascentage Pharma Releases Updated Lisaftoclax Data in MDS
    Ascentage Pharma Releases Updated Lisaftoclax Data in MDS

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharma-releases-updated-data-of-bcl-2-inhibitor-lisaftoclax-in-mds-that-demonstrates-potential-clinical-benefits-and-favorable-safety-302327621.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharmas-bcl-2-inhibitor-lisaftoclax-in-combinations-demonstrates-potential-clinical-benefit-in-patients-with-prior-exposure-to-venetoclax-302327542.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share